Does Rallies show Form 4 insider transactions for ANRO?

Yes. Rallies tracks ANRO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ANRO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ANRO. It does not provide personalized investment advice.

ANRO (Alto Neuroscience Inc.) Stock Analysis - Insider Trades

Alto Neuroscience Inc. (ANRO) is a publicly traded Healthcare sector company. As of May 21, 2026, ANRO trades at $20.77 with a market cap of $765.05M and a P/E ratio of -8.22. ANRO moved +1.71% today. Year to date, ANRO is +25.71%; over the trailing twelve months it is +614.09%. Its 52-week range spans $1.60 to $28.44. Analyst consensus is strong buy with an average price target of $35.22. Rallies surfaces ANRO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ANRO stock inside the company?

Recent ANRO insider activity includes Savitz Adam bought 2.93K, Savitz Adam bought 10.68K, Savitz Adam bought 1.39K, Smith Nicholas Conrad bought 1.60K, and Smith Nicholas Conrad bought 4.55K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ANRO Key Metrics

Key financial metrics for ANRO
Metric	Value
Price	$20.77
Market Cap	$765.05M
P/E Ratio	-8.22
EPS	$-2.50
Dividend Yield	0.00%
52-Week High	$28.44
52-Week Low	$1.60
Volume	2
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-61.43M
Gross Margin	0.00%

Recent ANRO Insider Trades

Savitz Adam bought 2.93K (~$38.75K) on Jul 10, 2024.
Savitz Adam bought 10.68K (~$133.83K) on Jul 9, 2024.
Savitz Adam bought 1.39K (~$18.25K) on Jul 9, 2024.
Smith Nicholas Conrad bought 1.60K (~$25.28K) on Mar 28, 2024.
Smith Nicholas Conrad bought 4.55K (~$75.35K) on Mar 28, 2024.

Latest ANRO News

Alto Neuroscience Initiates Phase 2b Trial, Secures $120M PIPE, $264M Cash — May 13, 2026
Alto Neuroscience Launches 178-Patient Phase 2b Trial of ALTO-207, Data in H2 2027 — Apr 21, 2026
Alto Neuroscience Secures $120M Financing, Jefferies Sees 41% Upside — Mar 16, 2026
Alto Neuroscience Among Five Firms as DEA Boosts Psilocybin Quota 67% — Feb 26, 2026

ANRO Analyst Consensus

11 analysts cover ANRO: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.22.

Common questions about ANRO

Who is trading ANRO stock inside the company?: Recent ANRO insider activity includes Savitz Adam bought 2.93K, Savitz Adam bought 10.68K, Savitz Adam bought 1.39K, Smith Nicholas Conrad bought 1.60K, and Smith Nicholas Conrad bought 4.55K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ANRO?: Yes. Rallies tracks ANRO insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ANRO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ANRO. It does not provide personalized investment advice.